These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15861261)

  • 1. Emergent decision-making: defining the patient perspective.
    Knudtson ML
    Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 4. Myocardial revascularization in acute myocardial infarction.
    Sharma S; Wasir HS
    J Assoc Physicians India; 1993 Feb; 41(2):103-9. PubMed ID: 8335599
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombolytic therapy in acute myocardial infarction: an emergency department perspective.
    Walters BL
    Henry Ford Hosp Med J; 1991; 39(3-4):184-94. PubMed ID: 1687142
    [No Abstract]   [Full Text] [Related]  

  • 6. [Repeat thrombolysis in acute myocardial infarction].
    Sychra M
    Vnitr Lek; 2002 Aug; 48(8):791-3. PubMed ID: 12425212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of reperfusion strategies.
    Parmley WW
    Am Heart J; 1999 Aug; 138(2 Pt 2):S142-52. PubMed ID: 10426873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 10. [Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction].
    Pereira H
    Rev Port Cardiol; 2000 Mar; 19(3):379-80. PubMed ID: 10804785
    [No Abstract]   [Full Text] [Related]  

  • 11. Stenting versus thrombolysis in acute myocardial infarction trial (STAT).
    Indian Heart J; 2001; 53(3):375. PubMed ID: 11516047
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 13. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R
    Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258
    [No Abstract]   [Full Text] [Related]  

  • 14. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [ln-hospital mortality after ST-segment elevation myocardial infarction according to reperfusion therapy].
    Prieto JC; Sanhueza C; Martínez N; Nazzal C; Corbalán R; Cavada G; Lanas F; Bartolucci J; Campos P;
    Rev Med Chil; 2008 Feb; 136(2):143-50. PubMed ID: 18483666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reperfusion therapy in acute myocardial infarct].
    Görge G; Haude M; von Birgelen C; Caspari G; Erbel R
    Dtsch Med Wochenschr; 1995 Mar; 120(11):375-82. PubMed ID: 7889820
    [No Abstract]   [Full Text] [Related]  

  • 17. Editor's commentary: One size does not fit all.
    Willerson JT
    Circulation; 2003 May; 107(20):2543-4. PubMed ID: 12777319
    [No Abstract]   [Full Text] [Related]  

  • 18. ST-segment-elevation myocardial infarction: guidelines and the challenge of real-world patient care.
    Spinler SA
    Pharmacotherapy; 2006 Aug; 26(8 Pt 2):115S-122S. PubMed ID: 16863477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Residual stenosis after intracoronary thrombolysis and usefulness of delayed angioplasty].
    Naruse H; Ishii J
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():479-83. PubMed ID: 12735019
    [No Abstract]   [Full Text] [Related]  

  • 20. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction?
    Dragu R; Behar S; Sandach A; Boyko V; Kapeliovich M; Rispler S; Hammerman H
    Am J Cardiol; 2006 Apr; 97(8):1142-5. PubMed ID: 16616015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.